FAITH - Factor XA Inhibitor-Related InTracranial Haemorrhage (FAITH)

A Real-World, Observational, Multicentre Retrospective Analysis to Evaluate the Clinical Characteristics, Medical Management and Outcomes of Hospitalised Patients With Factor XA Inhibitor-Related InTracranial Haemorrhage (FAITH)

FAITH study is a multicentre retrospective analysis study that aims to understand the burden of ICH related to FXa inhibitors and the current treatment approaches in country/countries where specific reversal agents are not available yet. The results of this analysis will improve our understanding of FXa inhibitor-related ICH, its socioeconomic impact and factors associated with negative outcomes in real-world settings. The insights gained can inform clinical decision making and potentially lead to strategies to optimise the use of FXa inhibitors, increase the availability of specific reversal agents and improve patient safety and outcomes.

Study Overview

• Status: Completed
• Conditions: InTracranial Haemorrhage

Detailed Description

FAITH is a retrospective, non-interventional, multicentre cohort study that will retrieve the data from medical records of adult patients who were hospitalised with confirmed diagnosis of ICH while being treated with FXa inhibitors. The primary objectives of the study is to describe the characteristics and hospital outcomes of hospitalised patients with FXa inhibitors-related ICH in real-world settings. Data of consecutive patients admitted on or after 1 January 2021 and by 30 June 2023 will be retrieved. The index date is defined as the date of hospital admission.The identification of ICH will be based on the CT/MRI scan records and according to the ICD-10-CM diagnosis code. To establish the causal relation between FXa and ICH, the study will include only patients who were determined in the medical records to have taken oral FXa inhibitors.The historical data will be followed up from the index date (the date of hospital admission) until the earliest date of death, lost to follow-up or up to 6 months.The 6-month follow-up period will allow for the assessment of the disability rate and the need for supportive care among survivors.

• Study Type: Observational
• Enrollment (Actual): 123

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina
    • Research Site
• Brazil
  • Joinville, Brazil
    • Research Site
  • Porto Alegre, Brazil
    • Research Site
• Colombia
  • Bogotá, Colombia
    • Research Site
• Mexico
  • Mexico City, Mexico
    • Research Site
• Qatar
  • Doha, Qatar
    • Research Site
• Saudi Arabia
  • Mecca, Saudi Arabia
    • Research Site
  • Riyadh, Saudi Arabia
    • Research Site
• United Arab Emirates
  • Abu Dhabi, United Arab Emirates
    • Research Site
  • Al Ain City, United Arab Emirates
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The study will recruit 350 adult patients (age ≥18 years at the time of hospital admission) hospitalised patients with FXa inhibitors-related ICH from a total of 20-25 sites from Asia-Pacific Region, Latin America, and the MEA, where FXa inhibitors specific reversal agent is not approved locally.

Description

Inclusion Criteria:

• Men and women ≥ 18 years of age at the time of hospital admission.
• Patients presented with a spontaneous or traumatic haemorrhage into any intracranial compartment. The diagnosis of ICH will be based on Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan and according to the ICD-10-CM diagnosis code.
• Patients who were determined in the medical records to have taken a dose of oral FXa inhibitors within 24 hrs before hospital presentation that warranted reversal of anticoagulant activities.

Exclusion Criteria:

• Patients who were treated with andexanet alfa.
• Patients who were enrolled in any clinical trials during the study period.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient characteristics	Age of the patients at the time of hospital admission (years) is recorded on Index day within 24 hours of hospitalization	Index day (Date of hospitalization) to 24hours
Patient Characteristics	Race (Middle Eastern, Asian, other) of the eligible patients is collected	Index day (Date of hospitalization) to 24hours
Sociodemographic Characteristics of eligible patients	Sociodemographic characteristics like Sex (Male or Female) of the eligible patients is recorded on Index day	Index day (Date of hospitalization) to 24hours
Sociodemographic Characteristics	Sociodemographic characteristics like nationality of the eligible patients info is collected on Index day	Index day (Date of hospitalization) to 24hours
Clinical characteristics	Comorbidities info of the eligible patients is recorded on Index day	Index day (Date of hospitalization) to 24hours
Clinical Characteristics	Clinical characteristics like BMI in Kg/m2 of the eligible patients is recorded on Index day	Index day (Date of hospitalization) to 24hours
FXa inhibitor characteristics	At index date the following FXa inhibitor characteristics will be described : Indication ,type and dose pf FXa Inhibitor	Time of last Fxa inhibitor dose to the time of hospital admission of maximum 24 hours
ICH characteristics	The primary ICH characteristics like type, site and presence of multicompartment haemorrhage during hospitalisation from Index date to 24hours	Index day to 1 week
GCS score	The GCS is scored between 3 and 15. 3 being the worst and 15 the best. It is composed of three parameters: best eye response (E), best verbal response (V), and best motor response (M)	Index day to 24hours
mRS score	mRS score recorded within 24 hours on Index date The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or others causes of neurological disability. It is scored from: 0=No symptoms at all; No significant disability; Slight disability; Moderate disability; Moderately severe disability 5=Severe disability 6=death	Index day to 24 hours
NIHSS score	NIHSS score recorded within 24 hours on the Index date Scores range from 0 to 42, with higher scores indicating greater severity. Stroke severity may be stratified on the basis of NIHSS scores as follows: Very Severe: >25 Severe: 15 - 24 Mild to Moderately Severe: 5 - 14 Mild: 1 - 5	Index date up to 24 hours
Haematoma volume	Haematoma volume based on baseline Imaging scans taken within 24 hours on the index date	Index day to 24 hours
BP (Systolic and Diastolic)	BP at Index date during hospital admission and in 6, 24, and 72 hours	Index day to 72 hours
Antihypertensive treatment	Antihypertensive treatment patterns during hospitalisation from Index date to 1 week	Index day to 1 Week
In-hospital mortality due to any cause	Number of patients died between index date (date of hospitalization) to Hospital discharge (maximum of 1 week)	Index date up to the death event during hospital stay (maximum 1 week)
Mortality at 30 days, post index event	Number of patients died between index date (date of hospitalization) up to 30 days	Index date up to 30 days
Mortality at 3 months post index event	Number of patients died between index date (date of hospitalization) up to 3 months	Index date up to 3 months
Mortality at 6 months post index event	Number of patients died between index date (date of hospitalization) up to 6 months	Index date up to 6 months
Type of discharge disposition	During the period from the hospital discharge date up to death event or 6 months, whichever occurs first, the following type of hospital discharge disposition will be described for survivors like Home, inpatient rehabilitation facility, nursing home, other hospitals/medical centres	Hospital discharge to Maximum of 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time from symptoms onset to hospital admission	Time between the onset of the bleeding symptoms to admission of patient in hospital in hours.	Baseline (which is the date of hospitalization i.e. Index date) to a maximum of 24 hours
Time from Hospital admission to time taken to do Imaging scan	Time between patient hospital admission to the performing of Imaging scan in minutes, less than 1 hour	Index day (Date of hospitalization) to Maximum of one hour
Time from hospital admission to administration of any haemostatic therapy	Time between patient hospital admission to start of the any haemostatic therapy in minutes, in less than 1 hour	Index day (Date of hospitalization) to Maximum of one hour
Healthcare resource utilization during hospitalisation	The length of ICU stay of eligible patients in days from Index day to maximum of 1 week	Index day to maximum of 1 week
Length of hospitalisation in days	The length of hospitalisation of eligible patients in days from Index day to maximum of 1 week	Index day to maximum of 1 week
Disability rate among survivors	At hospital discharge (Maximum of 1 week from Index day) Modified Rankin Score (mRS) will be described Functional outcome assessed with the modified Rankin Scale (mRS) at hospital discharge .The mRS is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered of stroke or other causes of neurological disability. It is scored from: 0=No symptoms at all 1=No significant disability, 2=Slight disability 3=Moderate disability 4=Moderately severe disability 5=Severe disability 6=death	At hospital discharge (Maximum of 1 week from Index day)
Disability rate among survivors	At three months, after the index event (date of hospital admission) Modified Rankin Score (mRS) will be described.	Index day to 3 months
Health care resource utilization after hospital admission up to 6 months	From the index date to 6 months the following HCRU will be described: Need for supportive medical care ,type of supportive care (including rehabilitation services), inpatient rehabilitation, outpatient rehabilitation, including occupational therapists, speech and language pathologists, dietician, nurse, adaptive equipment, everything else.	Index date to 6 months
Health care resource utilization within 6 months after hospital discharge.	From the patient hospital discharge up to 6 months the following HCRU will be described: Number of inpatient readmissions after discharge and up to 6 months, Type of ward, Number of days of hospitalization Reason for readmission and Medications.	Hospital discharge up to 6 months
Disability rate among survivors	At six months after the index event (date of hospital admission) Modified Rankin Score (mRS) will be described.	Index day to Maximum of 6 months

Collaborators and Investigators

• Sponsor: AstraZeneca

Publications and helpful links

Helpful Links

• Redacted CSR synopsis

Study record dates

Study Major Dates

• Study Start (Actual): July 8, 2024
• Primary Completion (Actual): November 1, 2024
• Study Completion (Actual): November 1, 2024

Study Registration Dates

• First Submitted: March 4, 2024
• First Submitted That Met QC Criteria: May 16, 2024
• First Posted (Actual): May 17, 2024

Study Record Updates

• Last Update Posted (Estimated): October 27, 2025
• Last Update Submitted That Met QC Criteria: October 23, 2025
• Last Verified: August 1, 2025

More Information

Terms related to this study

• Keywords: ICH; Factor XA Inhibitor-Related InTracranial Haemorrhage; FXa; FAITH
• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Hemorrhage; Pathological Conditions, Signs and Symptoms; Intracranial Hemorrhages
• Other Study ID Numbers: D9603R00022

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No